MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
A
Pipeline Grade

Financial Position (from SEC Filings)

$232.2M
Cash & Equivalents
$167.4M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$12,166M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (1 Assets)

DrugPhaseIndications
RESMETIROM
REZDIFFRA 		APPROVED Cirrhosis, Liver, Drug Safety, Healthy, Hepatic Impairment, Heterozygous Familial Hypercholesterolemia, MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH, NASH (Nonalcoholic Steatohepatitis), Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Renal Impairment

Upcoming Catalysts

No upcoming catalysts detected for this company.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for MDGL.

SEC EDGAR Filings

All SEC filings for MADRIGAL PHARMACEUTICALS, INC. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.